HUE053654T2 - FGFR- és CMET-inhibitorok kombinációi a rák kezelésére - Google Patents

FGFR- és CMET-inhibitorok kombinációi a rák kezelésére

Info

Publication number
HUE053654T2
HUE053654T2 HUE15721129A HUE15721129A HUE053654T2 HU E053654 T2 HUE053654 T2 HU E053654T2 HU E15721129 A HUE15721129 A HU E15721129A HU E15721129 A HUE15721129 A HU E15721129A HU E053654 T2 HUE053654 T2 HU E053654T2
Authority
HU
Hungary
Prior art keywords
fgfr
cancer
combinations
treatment
cmet inhibitors
Prior art date
Application number
HUE15721129A
Other languages
English (en)
Hungarian (hu)
Inventor
Eleonora Jovcheva
Timothy Pietro Suren Perera
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of HUE053654T2 publication Critical patent/HUE053654T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE15721129A 2014-03-26 2015-03-26 FGFR- és CMET-inhibitorok kombinációi a rák kezelésére HUE053654T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14161835 2014-03-26

Publications (1)

Publication Number Publication Date
HUE053654T2 true HUE053654T2 (hu) 2021-07-28

Family

ID=50389857

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15721129A HUE053654T2 (hu) 2014-03-26 2015-03-26 FGFR- és CMET-inhibitorok kombinációi a rák kezelésére

Country Status (23)

Country Link
US (3) US10085982B2 (enExample)
EP (2) EP3848034B1 (enExample)
JP (2) JP6752715B2 (enExample)
KR (1) KR102479693B1 (enExample)
CN (1) CN106458999B (enExample)
AU (1) AU2015238301B2 (enExample)
BR (1) BR112016022056B1 (enExample)
CA (1) CA2943682C (enExample)
CY (1) CY1123930T1 (enExample)
DK (1) DK3122358T3 (enExample)
ES (2) ES2856482T3 (enExample)
HR (1) HRP20210338T1 (enExample)
HU (1) HUE053654T2 (enExample)
LT (1) LT3122358T (enExample)
MA (2) MA55696A (enExample)
MX (1) MX370099B (enExample)
PL (1) PL3122358T3 (enExample)
PT (1) PT3122358T (enExample)
RS (1) RS61536B1 (enExample)
RU (1) RU2715236C2 (enExample)
SI (1) SI3122358T1 (enExample)
SM (1) SMT202100115T1 (enExample)
WO (1) WO2015144804A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
SMT202100115T1 (it) 2014-03-26 2021-05-07 Astex Therapeutics Ltd Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
LT3353177T (lt) 2015-09-23 2020-08-25 Janssen Pharmaceutica Nv Tricikliniai heterociklai, skirti vėžio gydymui
MX378230B (es) 2015-09-23 2025-03-10 Janssen Pharmaceutica Nv 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer.
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
KR20220024145A (ko) * 2019-06-17 2022-03-03 인스티튜트 바이올로지 도스비아트차네이 임 마르셀레고 넨키에고 폴스카 아카데미아 나우크 뇌전증 발생의 예방 및/또는 치료를 위한 마리마스타트의 용도

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0763537A3 (en) 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
JP4130700B2 (ja) 1996-02-26 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗腫瘍剤含有組成物
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AU742739B2 (en) 1997-05-28 2002-01-10 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
DE60032910T3 (de) 1999-05-05 2010-07-29 Institut Curie Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
MXPA02001108A (es) 1999-09-15 2002-08-20 Warner Lambert Co Pieridinonas como inhibidores de la cinasa.
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030235628A1 (en) 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
PL211694B1 (pl) 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
EP1496896A4 (en) 2002-04-08 2007-10-31 Merck & Co Inc AKT INHIBITORS EFFECT
US6962995B2 (en) 2002-07-10 2005-11-08 E. I. Du Pont De Nemours And Company Charge transport compositions and electronic devices made with such compositions
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
WO2004030635A2 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
EP1559433A4 (en) 2002-10-22 2009-11-04 Dainippon Sumitomo Pharma Co STABILIZED COMPOSITION
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
PT1636228E (pt) 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
AU2004259000A1 (en) 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for PPAR
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
PT1673092E (pt) 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
EA012621B1 (ru) 2003-11-07 2009-10-30 Чирон Корпорейшн Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
MXPA06005687A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
CA2545992A1 (en) 2003-11-24 2005-06-16 F. Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
WO2005061463A1 (en) 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
CN101048388A (zh) 2004-08-31 2007-10-03 阿斯利康(瑞典)有限公司 喹唑啉酮衍生物及其作为B－Raf抑制剂的用途
KR100875408B1 (ko) 2004-10-14 2008-12-23 에프. 호프만-라 로슈 아게 Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논
CA2583096A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
CA2589993C (en) 2004-12-09 2012-07-03 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
MX2007008141A (es) 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
AU2006212726C1 (en) 2005-02-14 2013-05-16 Bionomics Limited Novel tubulin polymerisation inhibitors
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
CA2606017A1 (en) 2005-05-12 2006-11-23 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2606598C (en) 2005-05-13 2014-12-23 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors
CN101223170A (zh) 2005-05-18 2008-07-16 惠氏公司 Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
CA2618479C (en) 2005-08-26 2014-12-30 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
JP5270353B2 (ja) 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
CN1966500B (zh) 2005-11-17 2011-03-30 中国科学院上海药物研究所 一类喹喔啉类衍生物、制法及用途
WO2007061130A1 (ja) 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
NZ568807A (en) * 2005-12-21 2011-05-27 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
CA2653117A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituted pteridines substituted with a four-membered heterocycle
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CA2657702A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg Quinazolines and related heterocyclic comp0unds, and their therapeutic use
US20100075947A1 (en) 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
US8148361B2 (en) 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc １，５−ナフチリジン化合物及び有機発光素子
PL2497470T3 (pl) 2006-11-22 2016-04-29 Incyte Holdings Corp Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy
AU2007334456A1 (en) 2006-12-13 2008-06-26 Merck Sharp & Dohme Corp. Methods of cancer treatment with IGF1R inhibitors
CA2673736A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
JP2010514693A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
EP2154965A4 (en) 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PL2172450T3 (pl) 2007-06-20 2014-03-31 Mitsubishi Tanabe Pharma Corp Nowe pochodne sulfonamidowe kwasu malonowego i ich zastosowanie farmaceutyczne
US8629144B2 (en) * 2007-06-21 2014-01-14 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
JP2010532758A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 組み合わせ抗癌療法
EP2188292B1 (en) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
EP2173354A4 (en) 2007-08-09 2011-10-05 Glaxosmithkline Llc CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
WO2013173485A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancers
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
PE20120029A1 (es) 2008-11-15 2012-02-13 Rib X Pharmaceuticals Inc Composiciones antimicrobianas
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
AU2010206161B2 (en) 2009-01-21 2014-08-07 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
AU2010208480A1 (en) 2009-02-02 2011-07-28 Msd K.K. Inhibitors of Akt activity
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
CN106905232B (zh) 2009-06-12 2019-09-27 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
JP5696856B2 (ja) 2009-09-03 2015-04-08 バイオエナジェニックス Ｐａｓｋの阻害用複素環式化合物
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
CR20170078A (es) 2009-09-18 2017-05-22 Sanofi Sa Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
SG184243A1 (en) 2010-03-30 2012-10-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2575462B1 (en) 2010-05-24 2016-06-22 Intellikine, LLC Heterocyclic compounds and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) * 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
CA2846574C (en) 2011-08-26 2020-07-07 Neupharma, Inc. Quinoxaline sulfonamide derivates for use as kinase inhibitors
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
WO2013089882A2 (en) 2011-09-27 2013-06-20 The Regents Of The University Of Michigan Recurrent gene fusions in breast cancer
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
ES2587533T3 (es) 2011-10-28 2016-10-25 Novartis Ag Derivados de purina y su uso en el tratamiento de enfermedades
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
AU2013228389A1 (en) 2012-03-08 2014-09-25 Astellas Pharma Inc. Novel FGFR3 fusion product
RU2014143213A (ru) 2012-04-03 2016-05-27 Новартис Аг Соединения ингибитора тирозинкиназы и их применение
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014007369A1 (ja) 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
HK1209343A1 (en) 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EP2877854B2 (en) 2012-07-24 2025-06-04 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
RU2015102194A (ru) 2012-07-27 2016-09-20 Дженентек, Инк. Способы лечения связанных с fgfr3 состояний
EP2902489B9 (en) 2012-09-27 2018-02-07 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
EP2981621B1 (en) 2013-04-05 2019-05-22 Life Technologies Corporation Gene fusions
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US20160186269A1 (en) 2013-05-27 2016-06-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
JP6182262B2 (ja) 2013-06-14 2017-08-16 シントン・ベスローテン・フェンノートシャップ 抗がん剤を含む安定な水溶性医薬組成物
WO2014201111A1 (en) 2013-06-14 2014-12-18 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
US9783853B2 (en) 2013-07-12 2017-10-10 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
US10028956B2 (en) * 2013-08-02 2018-07-24 Ignyta, Inc. Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
SMT202100115T1 (it) 2014-03-26 2021-05-07 Astex Therapeutics Ltd Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
SG11201706727XA (en) 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN105030777B (zh) 2015-07-14 2017-07-21 中国人民解放军第三军医大学第三附属医院 增强alk‑tki疗效、延缓其耐药的复合物及其制剂
CN105147687A (zh) 2015-09-28 2015-12-16 青岛华之草医药科技有限公司 一种治疗白血病的药物达沙替尼组合物胶囊
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
SMT202100115T1 (it) 2021-05-07
EP3122358A1 (en) 2017-02-01
RU2715236C2 (ru) 2020-02-26
KR20160136438A (ko) 2016-11-29
HRP20210338T1 (hr) 2021-04-30
JP6752715B2 (ja) 2020-09-09
DK3122358T3 (da) 2021-03-08
JP7296906B2 (ja) 2023-06-23
US11918576B2 (en) 2024-03-05
ES3014202T3 (en) 2025-04-21
MA39784B1 (fr) 2021-03-31
PT3122358T (pt) 2021-03-04
RS61536B1 (sr) 2021-04-29
US20180296558A1 (en) 2018-10-18
CA2943682C (en) 2024-02-13
MX370099B (es) 2019-12-02
US20210038598A1 (en) 2021-02-11
CN106458999A (zh) 2017-02-22
JP2017512791A (ja) 2017-05-25
MA39784A (fr) 2017-02-01
LT3122358T (lt) 2021-04-12
WO2015144804A1 (en) 2015-10-01
AU2015238301A1 (en) 2016-11-10
EP3848034A1 (en) 2021-07-14
KR102479693B1 (ko) 2022-12-22
BR112016022056A2 (enExample) 2017-08-22
CN106458999B (zh) 2019-12-03
RU2016141569A3 (enExample) 2018-11-02
CA2943682A1 (en) 2015-10-01
MX2016012365A (es) 2017-02-23
US10085982B2 (en) 2018-10-02
BR112016022056B1 (pt) 2023-04-11
EP3848034C0 (en) 2025-02-12
PL3122358T3 (pl) 2021-06-14
MA55696A (fr) 2022-02-23
CY1123930T1 (el) 2022-05-27
ES2856482T3 (es) 2021-09-27
JP2020114825A (ja) 2020-07-30
EP3122358B1 (en) 2020-12-16
US10716787B2 (en) 2020-07-21
AU2015238301B2 (en) 2020-06-25
SI3122358T1 (sl) 2021-04-30
EP3848034B1 (en) 2025-02-12
US20170119763A1 (en) 2017-05-04
RU2016141569A (ru) 2018-04-26

Similar Documents

Publication Publication Date Title
IL284727B (en) Noise suppression methods and apparatus
IL296080B1 (en) Method for treating cancer
HUE053654T2 (hu) FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
IL257880B (en) Beta-lactamase inhibitors
IL255261A0 (en) Methods for treating cancer
IL249476A0 (en) Combined treatment with glutaminase inhibitors
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
DK3240801T3 (da) Kombinationstumorimmunterapi
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE062158T2 (hu) EZH2 inhibitorok a limfóma kezelésére
HUE045511T2 (hu) A ror-gamma dihidro-pirrolopiridin inhibitorai
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3164380T (lt) Lizinui specifiniai demetilazės-1 inhibitoriai
IL254876A0 (en) Treatment of lung cancer with inhibitors of glutaminase
HUE038541T2 (hu) Rák kezelési módszerek
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
IL261047A (en) Taf1 inhibitors for the therapy of cancer
DK3215607T3 (da) Phagterapi
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
HUE040167T2 (hu) Rákkezelés